Stifel Nicolaus Keeps Their Buy Rating on Spark Therapeutics

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE), with a price target of $76. The company’s shares closed yesterday at $69.77.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 21.7% and a 51.5% success rate. Willey covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Alexion Pharmaceuticals, and Akcea Therapeutics Inc.

Currently, the analyst consensus on Spark Therapeutics is Moderate Buy and the average price target is $78.50, representing a 12.5% upside.

In a report issued on April 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $103 price target.

See today’s analyst top recommended stocks >>

Based on Spark Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $46.37 million. In comparison, last year the company had a GAAP net loss of $52.29 million.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.